Triple Combination of Encorafenib, Cetuximab, and Nivolumab in MSS BRAFV600E Metastatic Colorectal Cancer - OncoDaily Triplet of encorafenib, cetuximab, and nivolumab shows 50% response and 22-month OS in MSS BRAFV600E mCRC.

Triple Combination of Encorafenib, Cetuximab, and Nivolumab in MSS BRAFV600E Metastatic Colorectal Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Encorafenib #Cetuximab #Nivolumab #ColorectalCancer #CRC #GIOnc

Encorafenib, cetuximab combination plus chemo boosts survival in colorectal cancer Encorafenib and cetuximab combined with chemotherapy improves progression-free and overall survival in BRAF V600E-mutated metastatic colorectal cancer.

From #ASCO25 - #Encorafenib and #cetuximab combined with chemotherapy improves progression-free and overall survival in BRAF V600E-mutated metastatic #ColorectalCancer.

Full story 👉 buff.ly/vqsPRlw

#OncSky #MedNews

Firma la petición En España cientos de pacientes con cáncer no pueden pagarse el tratamiento

El 18/6/23 inicié una recogida de firmas en @change.org para la financiación del #TratamientoCáncerColon con #Encorafenib. Este medicamento está autorizado por el Ministerio de Sanidad pero la Seguridad Social no lo financia. Su coste es de 6.000 € mensuales.
👇
www.change.org/p/14-pa%C3%A...

Pfizer drug acquired in $11B buyout confirms benefit in colon cancer The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval — boosting an oncology portfolio Pfizer is looking to for revenue growth.

Pfizer drug acquired in $11B buyout confirms benefit in colon cancer #BRaf #Encorafenib #braftovi www.biopharmadive.com/news/pfizer-...

Maria (Masha) Babak: FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer - OncoDaily Maria (Masha) Babak: FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer / Braftovi, cancer, cetuximab, colorectal

FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer - Maria (Masha) Babak
@thebabaklab.bsky.social
@fda.gov

oncodaily.com/blog/222646

#Braftovi #Cancer #Cetuximab #ColorectalCancer #FDA #Encorafenib #mCRC #mFOLFOX6 #OncoDaily #Oncology #Medicine #Health

FDA Grants Accelerated Approval to Encorafenib, Cetuximab, and mFOLFOX6 for BRAF V600E Metastatic Colorectal Cancer - OncoDaily FDA Grants Accelerated Approval to Encorafenib, Cetuximab, and mFOLFOX6 for BRAF V600E Metastatic Colorectal Cancer / BREAKWATER trial, cancer, cetuximab,

FDA Grants Accelerated Approval to Encorafenib, Cetuximab, and mFOLFOX6 for BRAF V600E Metastatic Colorectal Cancer
@fda.gov

oncodaily.com/insight/210177

#BREAKWATERtrial #Cancer #Cetuximab #ColorectalCancer #Encorafenib #FDA #mFOLFOX6 #OncoDaily #Oncology #Medicine #Health

#Encorafenib + #Ceruximab + mFOLFOX is approved in 1L for BRAFV600e based off #BREAKWATER

- ORR 61% vs 40%
- mDoR: 13.9mos vs 11.1mos
- AEs:GI tox, rash

#cansky #oncsky #gism